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Objective: Minimally invasive aortic valve replacement (MIAVR)
has been demonstrated as a safe and effective option but remains
underused. We aimed to evaluate outcomes of isolated MIAVR com-
pared with conventional aortic valve replacement (CAVR).
Methods: Data from The National Institute for Cardiovascular Out-
comes Research (NICOR) were analyzed at seven volunteer centers
(2006Y2012). Primary outcomes were in-hospital mortality and
midterm survival. Secondary outcomes were postoperative length of
stay as well as cumulative bypass and cross-clamp times. Propensity
modeling with matched cohort analysis was used.
Results: Of 307 consecutive MIAVR patients, 151 (49%) were
performed during the last 2 years of study with a continued increase in
numbers. The 307 MIAVR patients were matched on a 1:1 ratio. In the
matched CAVR group, there was no statistically signiﬁcant difference
in in-hospital mortality [MIAVR, 4/307,(1.3%); 95% conﬁdence in-
terval (CI), 0.4%Y3.4% vs CAVR, 6/307 (2.0%); 95%CI, 0.8%Y4.3%;
P = 0.752]. One-year survival rates in the MIAVR and CAVR groups
were 94.4% and 94.6%, respectively. There was no statistically sig-
niﬁcant difference in midterm survival (P = 0.677; hazard ratio, 0.90;
95% CI, 0.56Y1.46). Median postoperative length of stay was lower in
the MIAVR patients by 1 day (P = 0.009). The mean cumulative
bypass time (94.8 vs 91.3 minutes; P = 0.333) and cross-clamp time
(74.6 vs 68.4 minutes; P = 0.006) were longer in the MIAVR group;
however, this was signiﬁcant only in the cross-clamp time comparison.
Conclusions: Minimally invasive aortic valve replacement is a safe
alternative to CAVRwith respect to operative and 1-year mortality and
is associated with a shorter postoperative stay. Further studies are
required in high-risk (logistic EuroSCORE 9 10) patients to deﬁne the
role of MIAVR.
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(Innovations 2016;11:15Y23)
Interest in minimally invasive aortic valve replacement(MIAVR) has increased after the adoption of transcatheter
techniques to treat aortic stenosis and early feasibility studies
on sutureless valve techniques.1Y6 Numerousminimally invasive
surgical approaches for aortic valve replacement (AVR) have
been proposed including upper or lower hemisternotomy, right
parasternal minithoracotomy, and transverse sternotomy.7Y9
Many reports including prospective randomized studies and
meta-analyses have demonstrated advantages of these incisions,
which include reduced pain, reduced surgical trauma, less bleeding,
earlier functional recovery, reduced incidence of chest and sternal
wound infections, lower incidence of arrhythmias, shorter hospital
stay, improved cosmetics, and reduced costs.10Y15 Despite these
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potential advantages, there has been limited uptake of these
techniques with only 5% to 10% of isolated AVRs being
performed in the USA and across Europe.12,16,17 The potential
drawbacks of minimally invasive cardiac surgery are perceived
increases in operative and cross-clamp times that may place
patients at increased risk of adverse outcomes.
There are no clear data guiding clinical practice with
regard to which patient groups would beneﬁt from minimally
invasive approaches. The objective of this research was to
investigate the current real-world experience with MIAVR and
report contemporaneous multicenter results for MIAVR versus
a propensity-matched cohort of conventional AVRs (CAVRs)
within the same institutions.
METHODS
Data Source, Validation, and Study Population
Prospectively collected data were extracted from The
National Institute for Cardiovascular Outcomes Research,
National Adult Cardiac Surgery Audit (NACSA) database in
November 2013 for all adult cardiac surgery procedures
performed in the UK. As described elsewhere, reproducible
cleaning algorithms were applied to the database to clean the
data.18 Brieﬂy, duplicates were removed; transcriptional dis-
crepancieswere harmonized; conﬂicting data and extremevalues
were corrected or removed. The data are returned annually to
each unit for local validation as part of the NACSA program.
For this study, procedures were included if they corre-
sponded to an isolated AVR (conventional or minimally invasive)
performed in a participating hospitalwith a procedure date between
December 1, 2006, and November 30, 2012. Transcatheter aortic
valve implantations (TAVIs) were identiﬁed and excluded. Patients
were identiﬁed as having undergone MIAVR using pseudo-
anonymized National Health Service (NHS) or hospital numbers
supplied by each participating center; all other patients were as-
sumed to have undergone CAVR. Exclusion criteria for this study
were indication (or missing data) of nonelective surgery, previous
cardiac surgery, critical preoperative state, use of preoperative in-
travenous nitrates, and renal dysfunction (deﬁned as patient on
dialysis or preoperative serum creatinine 9 200 Kmol/L).
Follow-up data up until the point of discharge were
collected through the NACSA, with postdischarge survival
data collected through linkage to the Ofﬁce for National Sta-
tistics registry. For a small number of patients discharged alive
with no available record linkage, the patients were followed up
to the point of discharge only. Database variable deﬁnitions
used for the study are available at http://www.ucl.ac.uk/nicor/
audits/Adultcardiacsurgery/datasets, and variables generated
within this study predominately follow the deﬁnitions as given
by the EuroSCORE model.19
Outcome Measures
The primary outcomes for this study were (1) in-hospital
mortality deﬁned as death due to any cause during admission to
the base hospital for cardiac surgery and (2) midterm survival.
Secondary outcomes were postoperative length of stay (PLOS),
cumulative bypass time, and cumulative cross-clamp times.
Patients who died in the hospital on the day of surgery were
recorded as having a PLOS of 0.5 days.
Missing Data
All missing patient characteristic and preoperative data
were imputed using a chain equation method that generates
‘‘plausible’’ synthetic values for each missing risk factor. Be-
cause the amount of missing data were low, a single imputation
approach was preferred to multiple imputations. Variables used
in the imputation models included those listed in Table 1, a
hospital-level indicator and in-hospital mortality.20 Imputation
was implemented using the MICE package (version 2.18) in
R.21 All analyses from here onward are based on the imputed
data. Missing outcome data (bypass time, cross-clamp time,
PLOS) were evaluated on a case-complete basis.
Propensity Score Matching
A propensity-matched analysis was used to account
for inherent confounding.22 The propensity score model was
developed by ﬁtting a nonparsimonious multiple logistic re-
gression models with AVR type (minimally invasive vs con-
ventional) as the outcome variable with independent variables
as listed in Table 1. This model was used to calculate a pro-
pensity score for each record. Patients who received MIAVR
were then matched (1-to-1 matching) to patients who under-
went CAVR using nearest neighbor matching with a greedy
matching algorithm.
After matching, the balance between the two groups
was evaluated by comparing the patient and preoperative
characteristics using standardized differences and graphical
comparison of propensity score distributions. An absolute
standardized difference of less than 10% supports the as-
sumption of balance between the two groups.23 Propensity
matching and diagnostic checking were performed using the
MatchIt package in R (version 2.4-21).22
Statistical Analysis
In the matched groups, in-hospital mortality was com-
pared between the MIAVR and CAVR groups using Fisher
exact test. In addition, an odds ratio was estimated with a
corresponding 95% conﬁdence interval (CI). Midterm survival
was compared between the matched groups using Kaplan-
Meier survival curve methodology stratiﬁed on operation
type, and the log-rank test was used to test for differences
between them. The hazard ratio for MIAVR was also estimated
by ﬁtting a Cox proportional hazards regression model with
operation as the sole independent variable. Postoperative length
of stay was compared between the two groups using a two-sided
nonparametric Mann-Whitney U test. Cumulative cross-clamp
times and cardiopulmonary bypass (CPB) times were com-
pared using an independent samples t test.
For the analysis of outcomes in propensity scoreYmatched
groups, there is no general statistical consensus on whether an
independent or matched-pairs analysis should be applied.24,25
We primarily focus on the independent groups analysis;
however, as sensitivity analysis, the data have also been an-
alyzed using methodology suitable for a matched-pairs de-
sign. Namely, for in-hospital mortality, McNemar test is
used; for midterm survival-stratiﬁed log rank tests, strat-
ifying on the matched-pairs is used; for PLOS, the Wilcoxon
signed rank test is used; and for cross-clamp and CPB time
comparisons, a paired t test is applied. All analyses were
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performed in R version 3.0.2 (R Development Core Team,
Vienna, Austria).26 In all cases, a P G 0.05 was considered
signiﬁcant.
Operative Technique
The patients were operated on according to standard
AVR techniques. We report the St Thomas’ technique that
is typical of the minimally invasive strategy. The contrib-
uting units have minor variations to this technique and
differences dictated by patient-speciﬁc anatomical and physio-
logical factors.
The patients were anesthetized in the supine position and
intubated with a single-lumen endotracheal tube. Deﬁbrillator
pads were placed over the chest wall and back. A transvenous
TABLE 1. Patient Demographics and Risk Factors in the Unmatched and Propensity Matched MIAVR and CAVR Groups
Unmatched Matched
Overall MIAVR CAVR Overall MIAVR CAVR
n % n % n % $ n % n % n % $
Total, n 4163 100.0 307 7.4 3856 92.6 614 100.0 307 50.0 307 50.0
Propensity score*† 0.074 (0.040) 0.097 (0.049) 0.072 (0.039) 55.9 0.097 (0.049) 0.097 (0.049) 0.096 (0.049) 0.3
Study year* 3.7 (1.7) 4.1 (1.7) 3.6 (1.7) 25.4 4.0 (1.7) 4.1 (1.7) 4.0 (1.6) 2.5
Logistic EuroSCORE*‡ 0.060 (0.050) 0.061 (0.047) 0.060 (0.050) 1.4 0.061 (0.047) 0.061 (0.047) 0.061 (0.048) j0.5
logit(EuroSCORE)* j3.00 (0.75) j2.97 (0.73) j3.00 (0.76) 4.2 j2.98 (0.74) j2.97 (0.73) j2.98 (0.75) 1.4
Age, y* 68.6 (11.8) 68.7 (11.7) 68.6 (11.8) 1.1 68.7 (11.4) 68.7 (11.7) 68.8 (11.1) j0.2
Age 9 65 y 2725 65.5 204 66.4 2521 65.4 2.3 417 67.9 204 66.4 213 69.4 j6.3
BMI* 28.6 (5.5) 28.3 (5.6) 28.7 (5.5) j7.2 28.3 (5.7) 28.3 (5.6) 28.3 (5.8) j0.6
BMI*§ 850.4 (346.1) 829.9 (347.4) 852.1 (346.0) j6.4 832.4 (358.8) 829.9 (347.4) 834.8 (370.4) j1.4
Female 1778 42.7 144 46.9 1634 42.4 9.1 285 46.4 144 46.9 141 45.9 2.0
NYHA
I 603 14.5 40 13.0 563 14.6 j4.6 80 13.0 40 13.0 40 13 0.0
II 1653 39.7 85 27.7 1568 40.7 j27.6 172 28.0 85 27.7 87 28.3 j1.4
III 1646 39.5 167 54.4 1479 38.4 32.6 333 54.2 167 54.4 166 54.1 0.7
IV 261 6.3 15 4.9 246 6.4 j6.5 29 4.7 15 4.9 14 4.6 1.5
CCS
0 2438 58.6 181 59.0 2257 58.5 0.9 362 59.0 181 59.0 181 59.0 0.0
I 553 13.3 36 11.7 517 13.4 j5.1 72 11.7 36 11.7 36 11.7 0.0
II 769 18.5 67 21.8 702 18.2 9.0 133 21.7 67 21.8 66 21.5 0.8
III 309 7.4 20 6.5 289 7.5 j3.8 42 6.8 20 6.5 22 7.2 j2.6
IV 94 2.3 3 1.0 91 2.4 j10.8 5 0.8 3 1.0 2 0.7 3.6
Urgent 741 17.8 43 14.0 698 18.1 j11.2 86 14.0 43 14.0 43 14.0 0.0
Neurological dysfunction 108 2.6 6 2.0 102 2.6 j4.6 10 1.6 6 2.0 4 1.3 5.1
Extracardiac arteriopathy 259 6.2 19 6.2 240 6.2 j0.1 43 7.0 19 6.2 24 7.8 j6.4
Diabetes 606 14.6 42 13.7 564 14.6 j2.7 82 13.4 42 13.7 40 13.0 1.9
History of hypertension 2490 59.8 205 66.8 2285 59.3 15.6 414 67.4 205 66.8 209 68.1 j2.8
Pulmonary hypertension 54 1.3 3 1.0 51 1.3 j3.2 6 1.0 3 1.0 3 1.0 0.0
Recent MI 77 1.8 7 2.3 70 1.8 3.3 12 2.0 7 2.3 5 1.6 4.7
History of pulmonary disease 586 14.1 52 16.9 534 13.8 8.6 107 17.4 52 16.9 55 17.9 j2.6
LVEF
950% 3318 79.7 235 76.5 3083 80.0 j8.3 475 77.4 235 76.5 240 78.2 j3.9
30%Y50% 664 16.0 60 19.5 604 15.7 10.2 114 18.6 60 19.5 54 17.6 5.0
G30% 181 4.3 12 3.9 169 4.4 j2.4 25 4.1 12 3.9 13 4.2 j1.6
Hemodynamics
Stenosis 3211 77.1 237 77.2 2974 77.1 0.2 469 76.4 237 77.2 232 75.6 3.8
Regurgitation 414 9.9 37 12.1 377 9.8 7.3 74 12.1 37 12.1 37 12.1 0.0
Mixed 538 12.9 33 10.7 505 13.1 j7.2 71 11.6 33 10.7 38 12.4 j5.1
Bioprosthesis 3229 77.6 251 81.8 2978 77.2 11.2 510 83.1 251 81.8 259 84.4 j6.9
Infective endocarditis 65 1.6 2 0.7 63 1.6 j9.2 4 0.7 2 0.7 2 0.7 0.0
*Continuous variables reported as mean (SD).
†Calculated from the propensity score model. Not an independent variable itself.
‡Logistic EuroSCORE was not included in the propensity score. Instead logit-transformed EuroSCORE was included.
§Number of patients.
Standardized difference ($) is used to measure the degree of balance between the MIAVR and CAVR cohorts before and after matching.
BMI, body mass index; CAVR, conventional aortic valve replacement; CCS, Canadian Cardiac Society; MI, myocardial infarction; MIAVR, minimally invasive aortic valve re-
placement; NYHA, New York Heart Association.
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pacing system was inserted at some centers via the internal
jugular vein. Transesophageal echocardiography was used
routinely in most cases to allow assessment of aortic valve
anatomy, annular sizing, deairing, and assessment of post-
operative valve and cardiac function. After skin preparation
and draping, a 4- to 6-cm skin incision usually an upper J
hemisterntomy through the third or fourth intercostal space
was performed. To enable smaller venous cannulae, vacuum-
assisted drainage was used in some patients. A triple-stage
venous cannula was used in most cases, placed in the superior
vena cava. Some patients necessitated peripheral cannulation,
depending on body habitus and cardiac anatomy. The aorta was
cannulated for arterial return. The majority of cases used mild
hypothermic 32-C to normothermic CPB with aortic cross-
clamping. Antegrade blood cardioplegia was used in most
cases. Aortic valve replacement was performed using inter-
rupted or semicontinuous technique as per surgeon preference.
Before closure of the aorta, the operative ﬁeldwas ﬂoodedwith
CO2 to minimize the chance of air embolism. The lungs were
also inﬂated to expel air from the left ventricle and aorta.
Deairing was monitored using transesophageal echocardiog-
raphy. On completion, the patient was decannulated, and
ventricular pacing wire was placed. The sternum was closed
with wires behind a standard chest or Blake drain. The wound
was closed in layers.
RESULTS
Data Set and Demographics
After applying the study inclusion and exclusion criteria,
a ﬁnal cohort of 4163 procedures was identiﬁed (307 MIAVR
and 3856 CAVR). Full details are provided in the data ﬂow
diagram in Figure 1. The proportion of missing data was less
than 2% for all patient and operative characteristics, with the
exception of neurological dysfunction (5.0%) and pulmonary
hypertension (2.7%). Outcomes were complete as follows: in-
hospital mortality for all records (100%), postdischarge dis-
charge follow-up survival data in 4088 records (98.2%), PLOS
in 4123 records (99.0%), as well as cumulative bypass and
cross-clamp times present in 4098 (98.4%) and 4103 (98.6%)
records, respectively.
The proportion of AVRs performed as MIAVR cases
at the participating hospitals doubled during the 6-year study
period from 5.3% to 10.0% (Fig. 2). Of the seven units in-
cluded, there was one outlying center that performed 25.3% of
AVR cases as MIAVR, whereas the others performed between
1.5% and 9.3% of cases as MIAVR (Fig. 3). The distributions
of logistic EuroSCORE in the MIAVR and CAVR cohorts have
remained comparable throughout the study (Supplementary
Digital Content, http://links.lww.com/INNOV/A71).
Propensity Score Matching
All 307 MIAVR records were matched to 307 CAVR
records. A summary of patient demographics and risk factors
before and after propensity matching based on imputed data is
given in Table 1. Before matching, there was imbalance in
study year, with a 25.4% standardized difference in favor ofFIGURE 1. Flow diagram demonstrating patient selection,
inclusion, and exclusions.
FIGURE 2. The yearly percentage of AVRs performed as
MIAVR across all centers during the study period. AVR, aortic
valve replacement; MIAVR, minimally invasive aortic valve
replacement.
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MIAVR, as an increasing number of MIAVR cases being
performed in the latter half of the study; proportion of pa-
tients in New York Heart Association class IV (6.5), Canadian
Cardiac Society IV (10.8), clinically urgent (11.2), being
treated for infective endocarditis (9.2), or with neurological
symptoms (4.6) was higher in the CAVR group. However,
the absolute standardized differences were small (G7%) for
all variables after matching, and so the two cohorts were
considered adequately balanced (Table 1). The distributions of
propensity scores before and after matching are more closely
aligned after matching.
In-Hospital Mortality Analysis
For the matched groups, there was no statistically sig-
niﬁcant difference in in-hospital mortality between the two
groups (P = 0.663): CAVR, 6/307 (2.0%; 95% CI: 0.8%Y4.3%)
versus MIAVR, 4/307 (1.3%; 95% CI, 0.4%Y3.4%), yielding
anodds ratio of 0.66 (95%CI, 0.19Y2.37) forMIAVR. Inferences
were unchanged using matched-pairs analysis (P = 0.752).
Survival Analysis
Five records in the CAVR propensity-matched group
could not be linked to the Ofﬁce for National Statistics death
registry. These records were therefore censored at point of
discharge. Sensitivity analyses with the exclusions did not
result in any changes in inferences. The median follow-up time
was 2.6 years (interval range, 2 days to 6.7 years). There was no
signiﬁcant difference in midterm survival between the matched
MIAVR and CAVR groups as shown in Figure 4 (P = 0.677).
The estimated hazard ratio in the matched groups was 0.90
(95% CI, 0.56Y1.46). Survival at 1 year in the MIAVR group
was 94.4% (95% CI, 91.9%Y97.0%) and in the CAVR group
was 94.6% (95% CI, 92.1%Y97.2%). Survival at 5 years in the
MIAVR group was 87.5% (95% CI, 83.1%Y92.2%) and in the
CAVR group was 85.5% (95% CI, 80.4%Y91.0%). Inferences
were unchanged using matched-pairs analysis (P = 0.668).
Secondary Outcomes
Postoperative length of stay was signiﬁcantly longer in
the CAVR matched group, with a difference in median values
of 1 day (P = 0.004) (Table 2). Inferences were unchanged
using matched-pairs analysis (P = 0.009). The mean cross-
clamp and CPB times were 6.3 and 3.5 minutes longer for
the MIAVR group, respectively (Table 2, Fig. 5); however,
this difference was only signiﬁcant for the cross-clamp times
(P = 0.006 and P = 0.333, respectively). Inferences were
unchangedusingmatched-pairs analysis (P=0.010andP=0.355,
respectively).
DISCUSSION
This study demonstrates that MIAVR has comparable
outcomes with those of CAVR with regard to in-hospital mor-
tality and midterm survival when analyzed at 1 and 5 years.
Small increases in cross-clamp andCPB times forMIAVRwere
demonstrated, but these are unlikely to have impact on out-
comes.A statistically signiﬁcant shorter PLOSwas present in the
MIAVR group. The strength of this study is the propensity-
matched comparative analysis of MIAVR outcomes. This study
combines contemporary national MIAVR experience to CAVR
experience at the same cardiac centers and thus provides accurate
real-world outcome data for MIAVR.
FIGURE 3. Volume of cases and rate of MIAVR across the
participating units. FRE, Freeman Hospital; HAM, Hammersmith
Hospital; MIAVR, minimally invasive aortic valve replacement;
MOR, Morriston Hospital; NCR, New Cross Hospital;
STH, St Thomas Hospital; STO, University Hospital of
North Staffordshire; VIC, Victoria Hospital.
FIGURE 4. Kaplan-Meier survival curves for the propensity
matched MIAVR and CAVR cohorts. Dashed lines indicate
approximate 95% conﬁdence intervals. CAVR, conventional
aortic valve replacement; MIAVR, minimally invasive aortic
valve replacement.
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We wrote to all centers in the UK to invite them to
participate in this study. Nine enthusiastic centers responded,
and seven are included where the data collected were robust
and complete; other units did not participate, and therefore, this
work represents a snapshot of contemporary practice in the UK.
The data demonstrates thatMIAVRs are increasingly performed,
with an increase in numbers as a total percentage of AVRs. The
proportion doubles during the study period.
Based on the results of this study, MIAVR is a safe al-
ternative to CAVR, with 98.6% of patients surviving to hospital
discharge. The reduction in PLOS in the MIAVR group may be
a surrogate marker for reduced postoperative complications.
Survival at 1 year exceeds 94% for both MIAVR and CAVR,
and there is no difference in midterm survival.
Although the percentage of MIAVRs increased during
the study period, MIAVR still represents a small proportion
of total caseload even at the enthusiastic centers participating
in this study. There are wide variations in the number of
centers undertaking MIAVR and the number of surgeons in-
volved at those centers. Practice is known to range between
surgeons who have a default minimally invasive approach
where all ﬁrst-time isolated AVRs are performed as minimally
invasive operations to those who exclusively perform CAVR.
There are areas of concern for cardiothoracic surgeons
regarding technique for CPB during MIAVR. These pertain to
the limited cardiac exposure that has numerous theoretical risks
(including placement of cannulae, adequate cardioplegia, and
cardiac venting). Limited exposure might limit assessment of
volume-loaded ventricles, deairing of the heart, placement of
pacingwires, or a retrogradecardioplegia cannula.Transesophageal
echocardiogram mitigates some of these problems, as well
as instillation of CO2 into the operative ﬁeld, anterior placement
of pacing wires, and manipulation of empty ventricles on CPB
to avoid right ventricular injury. The data do not allow us to
comment on the conversion rate to full sternotomy for technical
difﬁculties. Published data on conversions show it to be in the
region of 1% to 3%.13 In the presence of similar CPB and cross-
clamp times in our cohort, it is likely that the surgeons under-
taking the procedure have achieved the learning curve for
the techniques.
TABLE 2. The Cardiopulmonary Bypass and Cross-Clamp Times and Postoperative Length of Stay Across the Propensity-Matched
MIAVR and CAVR Cohorts
MIAVR CAVR
P
Independent Samples Analysis Matched-Pairs Analysis
PLOS,* median (Q1-Q3), d 6 (5Y8) 7 (5Y10) 0.004 0.009
CPB time,† mean (SD), min 94.8 (34.6) 91.3 (53.4) 0.333 0.355
Cross-clamp time,‡ mean (SD), min 74.6 (28.8) 68.4 (27.4) 0.006 0.010
*Two values were missing in the CAVR group.
†Five values were missing in the CAVR group and three values in the MIAVR group.
‡Five values were missing in the CAVR group and two values in the MIAVR group.
CAVR, conventional aortic valve replacement; MIAVR, minimally invasive aortic valve replacement; PLOS, postoperative length of stay; Q1, ﬁrst quartile; Q3, third quartile.
FIGURE 5. Kernel density distributions of cumulative CPB and cross-clamp times by AVR type in the propensity-matched cohort.
Note the horizontal axis is on a logarithmic-transformed scale to aid interpretation. AVR, aortic valve replacement; CPB,
cardiopulmonary bypass.
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There is apparent clinical equipoise between the two
techniques. Minimally invasive AVR is safe, and multiple
beneﬁts have been reported in retrospective, propensity-
matched, and randomized prospective studies. Previous stud-
ies of MIAVR have demonstrated reduced length of stay, with
no change in mortality or operative times.12,27 The meta-
analyses of multiple randomized trials have demonstrated de-
creased length of ITU stay and hospital stay,11,12 ventilation
times,10 blood loss,10,11 and incidence of arrhythmias10 as
well as improvement in pulmonary spirometry, sternal stability,
and wound pain.15,28 However, a need remains for large ade-
quately powered study to conclusively determine the advan-
tages of MIAVR and in which patient population these beneﬁts
apply to.
Intuitively, these advantages might specially apply to
higher-risk elderly patients with poorer physiological reserves
and who might tolerate minimally invasive procedure better
with a quicker recovery.29 The reasons for these reported
beneﬁts could be the maintenance of the bony continuity of the
ribcage with preservation of respiratory dynamics, improved
sternal stability, reduced pain, and less risk of chest and sternal
infections. There might also be a reduction in bleeding as less
bone marrow and periosteum are exposed with reduced cardiac
dissection during surgical access.
The role of minimally invasive techniques in surgical
AVR within the setting of sutureless valve technology and
TAVI needs to be deﬁned. Surgical AVR remains the criterion
standard for patients requiring AVR. At present, although
TAVI is only recommended for patients who are high-risk
for surgical AVR, data from German registries have begun
to demonstrate that ‘‘risk creep’’ is already occurring in
transcatheter aortic valve procedures with some centers ad-
vocating expanding TAVI to younger lower-risk groups.30 In
addition, a number of TAVI studies on intermediate-risk pa-
tients are on the way. The PARTNER II trial seeks to evaluate
outcomes in patients with aortic stenosis and The Society of
Thoracic Surgeons (STS) score of 4% to 6% and compare
patients to CAVR. Patients with concomitant coronary artery
disease will be randomized to percutaneous coronary inter-
vention plus TAVI versus coronary artery bypass graft surgery
plus AVR. As a noninferiority study, it will directly compare
CAVR with transaortic (TAo) TAVI, transapical (TA) TAVI,
or transfemoral-TAVI. Additional nested registries will also
analyze outcomes in patients who are unsuitable for femoral
access that are randomized to TA-TAVI or transaortic TAVI
versus surgery. This strategy will seek to marry the advantages
of the miniAVR access approach with balloon deployed TAVI
device. Similarly, the Surgical Replacement and Transcatheter
Aortic Valve Implantation (SURTAVI) trial will include pa-
tients older than 70 years with an STS score of 3% to 8%.
The stent valve evolution will deliver a greater range
of sizes of prosthesis through smaller totally percutaneous
delivery systems. Novel valve designs are currently in early
human studies to improve the incidence of paravalvular leak,
for instance, with the addition of sealing cuffs to variations of
nitinol frames.31 Numerous cerebral embolic protection de-
vices aim to catch debris from the aorta and reduce the neu-
rological morbidity from the procedure.32 Percutaneous closure
devices for femoral access vessels are being routinely used with
smaller delivery sheaths, and percutaneous left ventricular apex
closure is in animal testing stages.33
If surgeons are to remain actively engaged in the heart
valve team driving technical improvements in TAo and TA
techniques, this is likely to begin with assessing the impact
of MIAVR for surgical cases and likely to evolve into
completely minimally invasive/port access implantation of
transcatheter devices for high/intermediate-risk patients. One
of the centers involved in this study has an active TAo-TAVI
program, and it is likely that these techniques will develop in
parallel.34 The presence of the heart team at units undertaking
transcatheter valve procedures is increasing referrals of el-
derly comorbid patients now undergoing open AVR.2,35Y37
However, a recent decline in CAVR work has been observed
with up to 40% of aortic valve operations being performed by
TAVI in 2012.37,38
Other authors have commented on the fact that although
TAVI is an attractive and viable treatment for selected high-
risk patients (eg, porcelain aorta, truly frail patients, previous
cardiac surgery, patient grafts), surgical minimally invasive
access AVR should be regarded as a criterion standard for
all the rest of the patients. The functional outcomes are ex-
cellent, including valve durability, low incidence of stroke, and
no paravalvular leak, which are of paramount importance. For
octogenarians, the results of MIAVR are better than often as-
sumed.29,38 Even when MIAVR is performed in patients
with mean logistic EuroSCOREs of 17% (leading into the
accepted TAVI range), the midterm survival is good, with in-
hospital mortality of 7.8% and freedom from all-cause death
at 5 years at 72.4%.2,39 Outcomes in 175 octogenarians from a
cohort of more than 1000 MIAVR patients demonstrated an
operative mortality of 2%.13
Minimally invasive AVR might offer additional advan-
tages to the sutureless valve technologies that are perceived to
be an alternative treatment for high surgical risk patients with
severe aortic stenosis. Sutureless valves aim to minimize CPB
and cross-clamp times by using novel rapid valve deployment
techniques. One-year outcomes for the Edwards INTUITY
Valve System as part of the TRITON trial report MIAVR
in 48.8% of cases with overall cumulative survival of 92.5%
at 9.8 months. The CPB and cross-clamp times are reported as
75 minutes and 46.6 minutes with 54% of cases being isolated
AVRs.2,5 There are other INTUITY studies that are planned;
with CADENCE-MIS, the beneﬁts of MIAVR coupled with
rapid deployment valves will be studied versus CAVR and
standard valves. The use of Perceval S and ATS 3f Enable
has demonstrated similar reduction in bypass times of less than
30 minutes.3,40 Comparison with STS data show 60% decrease
in operative time, which might reduce the effects on myocardial
ischemia and hypoxia.27
Treatment of aortic valve disease is undergoing exciting
and rapidly expanding technological developments that offer
clinical and quality-of-life improvements to patients. A heart
valve multidisciplinary patient-centered approach is vital to
deliver best care to our patients.
Future Research
There seems to be genuine clinical equipoise between
MIAVR and CAVR. Before widespread adoption of MIAVR
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can be recommended, there is a need for a well-constructed,
adequately powered prospective randomized controlled study
comparing MIAVR with CAVR. To demonstrate differences in
mortality, the study would need to be powered to include very
large number of patients. Pragmatic approach would involve
high-risk patients in whom the clinical beneﬁts would be more
pronounced for the minimally invasive techniques. The bene-
ﬁts in terms of reduced ITU and hospital stay need to be bal-
anced against the costs of mini techniques. Although majority
of the procedure is performed using standard AVR equipment
and valves, trials are already underway to compare the impact
of sutureless valves. It is likely that the most beneﬁt from these
procedures will be in higher-risk elderly patients with limited
physiological reserves. Increased patient preference for mini-
mally invasive techniques and improvement in quality-of-life
surveys are also important end points that will need to be
considered in the randomized trials.
CONCLUSIONS
This propensity-matched study of minimally invasive
aortic valve surgery is based on multicenter, ‘‘real-world’’
experience and shows that MIAVR is a safe and feasible pro-
cedure with excellent early and midterm outcomes for patients
with aortic valve disease. In line with other authors, we have
shown beneﬁts in shorter hospital stay that might lead to more
widespread use.
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CLINICAL PERSPECTIVE
This study evaluated the outcomes of isolated minimally invasive aortic valve replacement (MIAVR) compared with con-
ventional aortic valve replacement (CAVR) by performing a propensity-matched study from the UK National Database. Data
were analyzed from seven volunteer centers from 2006 to 2012. Three hundred seven consecutive MIAVR patients were
matched in a 1:1 ratio with CAVR patients. There was no statistically signiﬁcant difference in the in-hospital mortality or 1-year
survival.Although therewas a signiﬁcantly longer cross-clamp time in theMIAVRgroup,medianpostoperative lengthof staywas
lower in the MIAVR patients by 1 day. The authors concluded that MIAVR was a safe alternative to CAVR with a shorter
postoperative length of stay.
This is an excellent multicenter study evaluating MIAVR. The propensity matching is a strength of this article but does not
fully compensate for selection bias. The authors recommended that a prospective, randomized study is needed to better
evaluate MIAVR. Although this is true, unfortunately, it will be difﬁcult for surgeons experienced in the minimally invasive
technique and for patients to be randomized between MIAVR and CAVR.
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